OnCo · weekly issue

OnCo weekly, 2026-09-15

14 changelog entries, 1 upcoming date, 20 publications, 89 corrections. Generated from the corpus; every item links to its page and, through it, to the primary source. Not medical advice.

What changed this week

New pages, new data and fixes, from the changelog.

Added: Molecule3D: ball-and-stick models of small molecules (CPK colours, shaded spheres, depth-sorted bond cylinders with double and triple bonds, drag to rotate, element legend) and smooth backbone ribbons for proteins (Catmull-Rom through the C-alpha trace, per-chain colours, wider on helices and strands, bound drug in ball-and-stick), with a wireframe toggle. Used on product pages, in every molecule thumbnail, and in a new "Solved structures with a drug bound" panel on target pages.
Added: PDB snapshots now keep secondary structure from the HELIX and SHEET records (ss); npm run fetch:structures -- --refresh-pdb 5A9U,5DK3 refreshes chosen entries without touching the rest.
Added: Startups and investors: company records gain optional stage, ycBatch, investors, funding (sourced rounds, amounts only where the source states them) and acquiredBy; companyType: "investor" for venture funds, corporate venture arms, an accelerator and disease foundations, whose portfolios are derived from backlinks.
Added: 62 Y Combinator companies attacking cancer, drawn from the open YC directory dataset and checked one by one (src/data/companies-yc.ts, snapshot with every hit and its decision in src/data/universe-lists/yc-oncology.json); 187 further venture-backed oncology companies across therapeutics, diagnostics, AI, digital care, radiotherapy hardware, surgery and tools (src/data/companies-startups.ts); 69 investors (src/data/investors.ts).
Added: /startups/ (stage strip, YC batch chips, filters by stage, modality, cancer, batch, investor and country, most active investors, recently funded) and /investors/; Funding panel on company pages, Portfolio panel on investor pages; stage and investor facets on /companies/; Startups and Investors in the Institutions & people group.

What changed in release 0.4.0 (2026-09-08)

New pages, new data and fixes, from the changelog.

Added: Animated wireframe schematics for all 18 fronts (front pages, Fronts index, home) and for all 19 glossary term categories (/terms/ and every term page).
Added: Molecule thumbnails wherever a product is mentioned: cards in pipelines, connected lists, and product tabs; hover popover with the rotating molecule on inline drug chips.
Added: Self-hosted organisation logos under public/logos/ (Wikimedia Commons via Wikidata with domain verification, favicon fallback) for companies, institutions, and collections.
Added: person kind (clinicians and scientists: role, specialisms, profiles, papers) with a People index and a People tab on institution pages.
Added: Site favicon and Apple touch icon; GitHub link in the header.
Added: Public-readiness: CI workflow, issue and pull-request templates, Code of Conduct, security policy, consolidated contributing guide.
Changed: Graph explorer rebuilt as a clean radial view (fronts inner ring, cancers outer ring) with a focus mode that groups neighbours by kind; no physics.
Changed: Header language and theme controls are single-line and compact.
Changed: Footer and About page carry the work-in-progress disclaimer: verify every fact at its primary source; not medical advice.

Upcoming readouts and decisions, next 30 days

Decisions, advisory committees, expected readouts and congresses from the readout calendar. Expected dates are editorial estimates.

2026-09-23 · FDA advisory committee: Galleri multi-cancer early detection test (PMA) (confirmed) · Galleri, GRAIL, Multi-cancer early detection (MCED), NHS-Galleri, PATHFINDER 2 · source

What the journals said, past 14 days

What the leading journals and regulators published, from the research pulse; every item links to the source.

2026-09-08 · Inhibrx claims first win for the long-sought OX40 target: Responses in head and neck cancer, strongest in HPV-positive tumours, after 15 years of failed OX40 programmes at big pharma. (Head and neck squamous cell carcinoma, Immune checkpoint inhibitors)
2026-09-08 · A breakthrough pancreatic cancer drug won approval. Patients still struggle to access it: Insurance barriers after the daraxonrasib approval. (Daraxonrasib, Pancreatic ductal adenocarcinoma)
2026-09-08 · Metabolic syndrome commonly develops in men on ADT plus ARPI: About 40% within a year, per the reported analysis. (Androgen deprivation & AR pathway inhibitors, Prostate cancer, Cardio-oncology)
2026-09-08 · Azacitidine/venetoclax boosts event-free survival in induction-eligible AML: Coverage of the NEJM head-to-head with intensive chemotherapy. (Azacitidine, Venetoclax, Acute myeloid leukaemia)
2026-09-08 · Alcohol-attributable cancer mortality has doubled in the US since 1990: Prevention story with policy implications. (Chemoprevention & risk-reducing surgery)
2026-09-08 · DeLLphi-305: durvalumab + tarlatamab meets OS in first-line maintenance ES-SCLC: 563 patients; first phase 3 T-cell engager OS win in first-line maintenance small-cell lung cancer; numbers pending a congress. (Tarlatamab, Durvalumab, DeLLphi-305, Small-cell lung cancer)
2026-09-08 · Arlocabtagene autoleucel meets primary endpoint in the QUINTESSENTIAL myeloma trial: The GPRC5D CAR-T advances toward filing. (GPRC5D, CAR-T cell therapy, Multiple myeloma)
2026-09-07 · KEYLYNK-001: pembrolizumab ± olaparib maintenance in BRCA-wild-type ovarian cancer: Vergote et al., 7 September: the immunotherapy plus PARP maintenance question in first line. (Pembrolizumab, Olaparib, Ovarian cancer, PARP inhibitors)
2026-09-07 · Lessons from one of the first randomised trials of AI in medicine: Lång, 7 September: what the MASAI mammography-AI trial taught about running AI trials. (AI in radiology, Mammography & tomosynthesis)
2026-09-07 · Oncology dealmaking is becoming more surgical: Buyers target specific modalities and assets rather than platforms. (Antibody-drug conjugate (ADC), Radioligand therapy (beta emitters))
2026-09-05 · Six first-in-class approvals in August, including Etcamah: Camizestrant counted among August's first-in-class approvals. (Camizestrant)
2026-09-04 · Accelerated approval: camizestrant + CDK4/6 inhibitor for ESR1-mutated HR+/HER2- breast cancer: Etcamah approved 4 September after a 6-3 negative advisory vote, on SERENA-6 ctDNA-guided switching data. (Camizestrant, SERENA-6, Estrogen receptor (ERα), HR-positive / HER2-negative breast cancer)
2026-09-04 · Etcamah grabs FDA approval for advanced breast cancer with ESR1 mutations: Camizestrant plus a CDK4/6 inhibitor, accelerated approval. (Camizestrant, HR-positive / HER2-negative breast cancer)
2026-09-04 · Targeting fibroblast activation suppresses chemotherapy-induced pro-invasive remodelling: Stroma as a therapeutic target after chemotherapy. (FAP, Epithelial-mesenchymal transition & drug efflux)
2026-09-03 · Daraxonrasib for previously treated RAS-mutant NSCLC: Arbour et al., 3 September: the pan-RAS inhibitor shows activity beyond pancreatic cancer. (Daraxonrasib, KRAS, Non-small-cell lung cancer)
2026-09-03 · Azacitidine-venetoclax or induction chemotherapy for AML: Fathi et al., 3 September: the chemotherapy-free doublet compared head to head with 7+3 in fit patients, with an accompanying editorial. (Azacitidine, Venetoclax, Acute myeloid leukaemia, VIALE-A)
2026-09-03 · Molecularly guided therapy vs chemotherapy in cancer of unknown primary (CUPISCO): Krämer et al., 3 September: genomics-directed treatment tested in a randomised trial. (Comprehensive genomic profiling, Companion diagnostics)
2026-09-03 · Pan-RAS inhibitor shows activity in advanced lung cancer: News digest, 3 September, on the NEJM daraxonrasib NSCLC data. (Daraxonrasib, KRAS, Non-small-cell lung cancer)
2026-09-03 · Daraxonrasib exhibits 'encouraging signal' in RAS-mutant metastatic lung cancer: The pancreatic drug's NEJM lung data. (Daraxonrasib, Non-small-cell lung cancer)
2026-09-03 · DLL3 expression predicts response and long-term outcome in SCLC: Biomarker work relevant to tarlatamab and DLL3 engagers. (DLL3, Tarlatamab, Small-cell lung cancer)

Corrections, past 7 days

Confirmed factual corrections to the corpus, with the fixing commit.

2026-09-13 · nct05208047: status was "recruiting"; the registry says RECRUITING; primary completion 2025-09-30. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · alphabreak: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · alphabreak: phase was "3"; the registry says PHASE2. (Weekly registry fact check (source)) · set to "2" via apply-factcheck
2026-09-13 · cambria: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Weekly registry fact check (source)) · set to "active" via apply-factcheck
2026-09-13 · mountaineer: status was "recruiting"; the registry says COMPLETED. (Weekly registry fact check (source)) · set to "completed" via apply-factcheck
2026-09-13 · mountaineer: phase was "3"; the registry says PHASE2. (Weekly registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · acupuncture-aromatase-inhibitor-arthralgia, retifanlimab, b-combination-space, basement-membrane-tissue-barriers, kenneth-kinzler, cbt-fatigue-distress, multidisciplinary-tumour-board: Seven cited DOIs did not resolve (mistyped or belonging to another article); the intended papers were re-identified through Crossref with journal and DOI prefix pinned, for example POD1UM-303 to 10.1016/S0140-6736(25)00631-2 and the FAP locus paper to 10.1126/science.1651562. Two more (rEECur, NUT carcinoma registry) could not be identified and were removed; the small bowel adenocarcinoma guideline DOI now points at the ASCO guidelines index. (Link check (doi.org 404)) · URLs corrected
2026-09-11 · 46 records with a Wikipedia link, 13 with a Wikipedia-only source: The Wikipedia article title in wikipedia or links no longer exists (for example Oncotype_DX, PSMA_PET, Immuno-PET). Titles were checked against the Wikipedia API; one was renamed (Biosecure Act), the rest removed. BCLC staging and cardio-oncology now cite their primary guideline papers instead. (Link check (404)) · references removed or replaced
2026-09-11 · 33 dead pages (fda.gov, cancer.gov, institutional and company pages): Pages returned 404 to a browser as well as to the checker; replaced with the nearest Wayback Machine snapshot and labelled "(archived copy)". 45 pages whose publisher moved them now point at the nearest live section of the same site, labelled "(page moved; nearest live section)"; 101 dead links on records that keep another source were removed. accessdata.fda.gov and doi.org answer non-browser clients with 404 or 403, so those were verified with a browser user agent and left as they were. (Link check) · URLs replaced or removed
2026-09-11 · elevate-tn: nct was NCT02475097, which does not exist on ClinicalTrials.gov; the acalabrutinib ELEVATE-TN study is NCT02475681 (acronym ElevateTN). (Registry fact check (nct-not-found), confirmed against the registry entry) · set to NCT02475681
2026-09-11 · ace-breast-02: nct was NCT04829604, which is the separate US phase 2 study ACE-Breast-03 (72 patients); ACE-Breast-02 is registered in China only. (Registry fact check: phase and enrolment disagreed, registry title names ACE-Breast-03) · id removed; the primary publication is the source
2026-09-11 · preopanc: nct was NCT02172976, a 40-patient German gemcitabine versus FOLFIRINOX study, not the Dutch PREOPANC trials. (Registry fact check: enrolment 40 versus 246 and a different title) · set to NTR3709 (Netherlands Trial Register) and cite the JCO 2020 and JCO 2022 papers
2026-09-11 · iberdomide: Status "phase-3" with no US approval; openFDA holds the Zenbexus label, effective 13 August 2026, for relapsed myeloma with daratumumab and dexamethasone. (Registry fact check (openFDA label exists, not recorded as approved)) · status approved, approvals row and DailyMed link added; regional table updated
2026-09-11 · daraxonrasib: regional-approvals.ts still said "under review" while the record and the FDA novel approvals page record approval on 26 August 2026 (Rasonque). (Audit (approvals disagree with the regional table)) · regional row set to approved 2026
2026-09-11 · nintedanib: Status "negative" although the EMA authorised Vargatef for lung adenocarcinoma with docetaxel in 2014; the mesothelioma failure is one programme, not the molecule's status. (Audit (status disagrees with approvals)) · status approved, EMA EPAR linked, TL;DR reworded
2026-09-11 · atrt, chordoma, epithelioid-sarcoma, epigenetics-roadmap: Standard-of-care rows, pipelines and a roadmap step still presented tazemetostat as available; Ipsen withdrew it from all markets in March 2026. (Audit (standard of care and pipeline cite a withdrawn item)) · rows reworded to state the withdrawal, removed from pipelines, roadmap step notes it
2026-09-11 · mds: Pipeline listed magrolimab, stopped in 2024. (Audit (pipeline cites a withdrawn item)) · removed
2026-09-11 · hairy-cell-leukemia: Row said moxetumomab pasudotox "where still available"; it was withdrawn from sale in 2023. (Audit (standard of care cites a withdrawn item)) · reworded
2026-09-11 · docetaxel, durvalumab, ibrutinib, lenalidomide, pegylated-liposomal-doxorubicin, temsirolimus, dabrafenib-trametinib: approvals[] began later than the first approval: docetaxel 1996 (Taxotere, breast), durvalumab 2017 (urothelial, accelerated), ibrutinib US 2013 (MCL) and EU 2014, lenalidomide 2005 (MDS del(5q)), Doxil 1995 (Kaposi sarcoma); temsirolimus EU year was 2009 (Torisel authorised November 2007, MCL added 2009); the dabrafenib plus trametinib combination was approved in the US in January 2014 (regional table said 2013, the single agents). (Audit (approvals disagree with the regional table) and Drugs@FDA earliest original approval) · rows added or corrected
2026-09-11 · lacc: Text quoted a death hazard ratio of 6.00 while the only structured outcome carried the disease-free survival HR 3.74. (Audit (number in the text disagrees with the structured field)) · overall survival outcome added from NEJM 2018
2026-09-11 · peace-1: Result gave only the overall-population OS HR 0.82 while the structured outcome carried the ADT plus docetaxel population HR 0.75. (Audit (number in the text disagrees with the structured field)) · result states both populations
2026-09-11 · bevacizumab, cabozantinib, everolimus, ivosidenib, lenvatinib, letrozole, ramucirumab, regorafenib, sunitinib, trabectedin, Eisai, Exelixis, Incyte: Each was defined in full by two or three cancer deep dives with different summaries, mechanisms and approval rows; only the first copy was ever shown and the rest were silently hidden. (Audit (duplicates with different values)) · second copies became supplements: relationship arrays, extra approval rows and cancer-specific facts as notes
2026-09-11 · alfa-0701: enrolled was "271"; the registry says 280 (ACTUAL). (Registry fact check (source)) · set to "280" via apply-factcheck
2026-09-11 · alter-0303: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · amplify-7p: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · apt-trial: enrolled was "410"; the registry says 406 (ACTUAL). (Registry fact check (source)) · set to "406" via apply-factcheck
2026-09-11 · ascertain-v: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · belinda: enrolled was "322"; the registry says 330 (ACTUAL). (Registry fact check (source)) · set to "330" via apply-factcheck
2026-09-11 · camel: enrolled was "412"; the registry says 419 (ACTUAL). (Registry fact check (source)) · set to "419" via apply-factcheck
2026-09-11 · cartitude-5: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · checkmate-9dw: enrolled was "668"; the registry says 732 (ACTUAL). (Registry fact check (source)) · set to "732" via apply-factcheck
2026-09-11 · checkmate-9er: enrolled was "651"; the registry says 701 (ACTUAL). (Registry fact check (source)) · set to "701" via apply-factcheck
2026-09-11 · cll14: enrolled was "432"; the registry says 445 (ACTUAL). (Registry fact check (source)) · set to "445" via apply-factcheck
2026-09-11 · anbl0532: enrolled was "652"; the registry says 665 (ACTUAL). (Registry fact check (source)) · set to "665" via apply-factcheck
2026-09-11 · compete: enrolled was "309"; the registry says 324 (ACTUAL). (Registry fact check (source)) · set to "324" via apply-factcheck
2026-09-11 · desktop-iii: enrolled was "407"; the registry says 408 (ACTUAL). (Registry fact check (source)) · set to "408" via apply-factcheck
2026-09-11 · destiny-breast12: enrolled was "504"; the registry says 506 (ACTUAL). (Registry fact check (source)) · set to "506" via apply-factcheck
2026-09-11 · dreamseq: enrolled was "265"; the registry says 267 (ACTUAL). (Registry fact check (source)) · set to "267" via apply-factcheck
2026-09-11 · emerald-3: enrolled was "725"; the registry says 760 (ACTUAL). (Registry fact check (source)) · set to "760" via apply-factcheck
2026-09-11 · epcore-nhl-1: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · foenix-cca2: phase was "2"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · golseek-1: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · her2climb-02: enrolled was "463"; the registry says 466 (ACTUAL). (Registry fact check (source)) · set to "466" via apply-factcheck
2026-09-11 · herizon-gea-01: enrolled was "914"; the registry says 920 (ACTUAL). (Registry fact check (source)) · set to "920" via apply-factcheck
2026-09-11 · horizon-breast01: enrolled was "366"; the registry says 381 (ACTUAL). (Registry fact check (source)) · set to "381" via apply-factcheck
2026-09-11 · imroz: enrolled was "446"; the registry says 475 (ACTUAL). (Registry fact check (source)) · set to "475" via apply-factcheck
2026-09-11 · inavo120: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · keynote-483: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · ion-trial: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · izabright-breast01: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · lacc: enrolled was "631"; the registry says 636 (ACTUAL). (Registry fact check (source)) · set to "636" via apply-factcheck
2026-09-11 · legend-2: phase was "1"; the registry says PHASE1/PHASE2. (Registry fact check (source)) · set to "1/2" via apply-factcheck
2026-09-11 · lidera: enrolled was "4200"; the registry says 4170 (ACTUAL). (Registry fact check (source)) · set to "4170" via apply-factcheck
2026-09-11 · litespark-005: enrolled was "746"; the registry says 755 (ACTUAL). (Registry fact check (source)) · set to "755" via apply-factcheck
2026-09-11 · lume-meso: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · maps: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · matterhorn: enrolled was "948"; the registry says 957 (ACTUAL). (Registry fact check (source)) · set to "957" via apply-factcheck
2026-09-11 · mevpro-1: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · orient-32: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · orient-32: enrolled was "571"; the registry says 595 (ACTUAL). (Registry fact check (source)) · set to "595" via apply-factcheck
2026-09-11 · outback: enrolled was "919"; the registry says 926 (ACTUAL). (Registry fact check (source)) · set to "926" via apply-factcheck
2026-09-11 · persevera: enrolled was "978"; the registry says 992 (ACTUAL). (Registry fact check (source)) · set to "992" via apply-factcheck
2026-09-11 · phergain: enrolled was "356"; the registry says 377 (ACTUAL). (Registry fact check (source)) · set to "377" via apply-factcheck
2026-09-11 · quilt-3-032: phase was "2"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · rxponder: enrolled was "5083"; the registry says 5018 (ACTUAL). (Registry fact check (source)) · set to "5018" via apply-factcheck
2026-09-11 · senticol-iii: status was "recruiting"; the registry says ACTIVE_NOT_RECRUITING. (Registry fact check (source)) · set to "active" via apply-factcheck
2026-09-11 · stellar: enrolled was "80"; the registry says 82 (ACTUAL). (Registry fact check (source)) · set to "82" via apply-factcheck
2026-09-11 · viale-a: enrolled was "431"; the registry says 443 (ACTUAL). (Registry fact check (source)) · set to "443" via apply-factcheck
2026-09-11 · waveline-003: phase was "3"; the registry says PHASE2/PHASE3. (Registry fact check (source)) · set to "2/3" via apply-factcheck
2026-09-11 · her2climb: phase was "3"; the registry says PHASE2. (Registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · imcgp100-202: phase was "3"; the registry says PHASE2. (Registry fact check (source)) · set to "2" via apply-factcheck
2026-09-11 · ken-she: phase was "3"; the registry says PHASE4. (Registry fact check (source)) · set to "4" via apply-factcheck
2026-09-11 · amplify-7p: enrolled was "144"; the registry says 158 (ACTUAL). (Registry fact check (source)) · set to "158" in trial-outcomes.ts
2026-09-11 · eortc-26981: enrolled was "573"; the registry says 575 (ACTUAL). (Registry fact check (source)) · set to "575" in trial-outcomes.ts
2026-09-11 · keynote-355: enrolled was "847"; the registry says 882 (ACTUAL). (Registry fact check (source)) · set to "882" in trial-outcomes.ts
2026-09-11 · litespark-012: enrolled was "1688"; the registry says 1854 (ACTUAL). (Registry fact check (source)) · set to "1854" in trial-outcomes.ts
2026-09-11 · pathfinder-2: enrolled was "35878"; the registry says 35883 (ACTUAL). (Registry fact check (source)) · set to "35883" in trial-outcomes.ts
2026-09-11 · rasolute-302: enrolled was "460"; the registry says 500 (ACTUAL). (Registry fact check (source)) · set to "500" in trial-outcomes.ts
2026-09-11 · tropion-breast03: enrolled was "1075"; the registry says 1174 (ACTUAL). (Registry fact check (source)) · set to "1174" in trial-outcomes.ts
2026-09-11 · tropion-lung01: enrolled was "604"; the registry says 605 (ACTUAL). (Registry fact check (source)) · set to "605" in trial-outcomes.ts
2026-09-11 · flaura2: enrolled was "557"; the registry says 587 (ACTUAL). (Registry fact check (source)) · set to "587" in trial-outcomes.ts
2026-09-11 · impassion131: enrolled was "651"; the registry says 653 (ACTUAL). (Registry fact check (source)) · set to "653" in trial-outcomes.ts
2026-09-11 · latitude: enrolled was "1199"; the registry says 1209 (ACTUAL). (Registry fact check (source)) · set to "1209" in trial-outcomes.ts
2026-09-11 · olympia: enrolled was "1836"; the registry says 1837 (ACTUAL). (Registry fact check (source)) · set to "1837" in trial-outcomes.ts
2026-09-11 · psmafore: enrolled was "468"; the registry says 469 (ACTUAL). (Registry fact check (source)) · set to "469" in trial-outcomes.ts
2026-09-11 · splash: enrolled was "412"; the registry says 455 (ACTUAL). (Registry fact check (source)) · set to "455" in trial-outcomes.ts
2026-09-11 · therap: enrolled was "200"; the registry says 201 (ACTUAL). (Registry fact check (source)) · set to "201" in trial-outcomes.ts
2026-09-11 · vision: enrolled was "831"; the registry says 861 (ACTUAL). (Registry fact check (source)) · set to "861" in trial-outcomes.ts
2026-09-11 · xalute: enrolled was "675"; the registry says 707 (ACTUAL). (Registry fact check (source)) · set to "707" in trial-outcomes.ts